Published in final edited form as:

Trends Pharmacol Sci. 2016 February ; 37(2): 87–100. doi:10.1016/j.tips.2015.10.005.

Cellular Biomechanics in Drug Screening and Evaluation: Mechanopharmacology

Ramaswamy Krishnan¹, Jin-Ah Park², Chun Y. Seow³, Peter V-S. Lee⁴, and Alastair G. Stewart^{5,*}

¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

²Harvard T.H. Chan School of Public Health, Boston, MA, USA

³Center for Heart Lung Innovation, St Pauls Hospital, University of British Columbia, Vancouver, Canada

⁴Department of Mechanical Engineering, University of Melbourne, Melbourne, Australia

⁵Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia

Abstract

The study of mechanobiology is now widespread. The impact of cell and tissue mechanics on cellular responses is well appreciated. However, knowledge of the impact of cell and tissue mechanics on pharmacological responsiveness, and its application to drug screening and mechanistic investigations, have been very limited in scope. We emphasize the need for a heightened awareness of the important bidirectional influence of drugs and biomechanics in all living systems. We propose that the term ‘mechanopharmacology’ be applied to approaches that employ *in vitro* systems, biomechanically appropriate to the relevant (patho)physiology, to identify new drugs and drug targets. This article describes the models and techniques that are being developed to transform drug screening and evaluation, ranging from a 2D environment to the dynamic 3D environment of the target expressed in the disease of interest.

Drug Screening and Evaluation: The Need To Consider Cellular Mechanics

The reasons for failure of drug development programs are the subject of much contemplation. Although adverse effects, toxicity, as well as pharmacokinetic features, are often cited as reasons for arrested drug development, several recent studies highlight failure because of lack of efficacy. A review of the portfolio performance of AstraZeneca in Phase IIa and IIb studies from 2005 to 2010 suggested that 57% and 88%, respectively, of the project closures at this stage were due to a failure of efficacy, whereas attrition due to lack of efficacy in the preclinical phase was as low as 6% [1]. There are many reasons to expect that preclinical and clinical pharmacology will differ, including the use of non-human species to

*Correspondence: astew@unimelb.edu.au (A.G. Stewart).

support efficacy. However, even when the target is expressed and engaged in human cell types, failure may ensue because the affected pathways are less influential than anticipated from the preclinical studies. When the agent reaches the target in adequate concentration and for a sufficient duration, giving a suitable level of drug exposure, lack of efficacy is likely to result from differences in behavior of the drug target in the assay systems compared with the target behavior *in situ* in the patient-specific context. The screening and preclinical pharmacology for many of these agents is likely to have been established in cell culture, in an oversimplified mechanical microenvironment, and/or in non-human models of the targeted disease. We argue that drug screening can be improved with the use of human cells of phenotype most relevant to the condition, ideally being derived from patients (representative of the disease stage being targeted), and then cultured in the most (patho)physiologically relevant conditions. This approach is intended to ensure that the assay emulates the biomechanical environment in the condition to be treated. Ideally, the assay would also embed cell mechanical measurements of deformability, stiffness, and/or contraction, as in many organs and diseases, because these cellular changes often constitute the principal endpoint of therapeutic intent. The use of patient-derived primary cell cultures improves the likelihood of genetic and epigenetic influences being appropriately expressed, with the expectation that the target efficacy would be more accurately predicted. It will be valuable to rigorously test this proposition against comparator preclinical efficacy testing in relevant animal models and in 2D culture on a rigid plastic substrate.

The impact of biomechanics on cell function has been systematically explored, leading to a broad appreciation of mechanosensitive processes, with the principal mechanosensors being selected ion channels [2•3] and less commonly the integrins [4]. Mechanotransduction involves force transmission through bound proteins resulting in conformational changes that entrain functional impacts. For example, conformational changes in vinculin and talin have been shown to subserve the recruitment of the actin cytoskeleton to focal adhesions in the leading edge of migrating cells [5•6].

The impact of biomechanics on drug actions is rarely addressed, despite being highlighted as an important consideration repeatedly in the literature (e.g., [7•8]). Recent advances proposed by Donald Ingber and colleagues using ‘organ-on-a-chip’ microfluidics technology involving cell cultures being subjected to cyclical strains (breathing/cardiac cycle/peritoneal peristalsis/renal fluidic shear) raise the prospect of more systematic and relevant drug discovery paradigms using human cell cultures [9•10]. Similarly, recent advances in cell mechanics have highlighted the suitability of mechanical endpoints as phenotypic targets in high-throughput screening [11]. In this article we develop selected examples of biomechanical impacts on cell function and drug responsiveness, and discuss refined, biomechanically appropriate bioassays, emphasizing those suitable for scaling to medium to high throughput.

We exemplify below the selected impacts of different aspects of the biomechanical environment (Box 1)

Shear Forces

The effects of shear are extensively explored in the cardiovascular system [7], but there are other organs where fluid and gas flows create shear forces that impact on cell and tissue function. Shear represents the frictional force exerted by flow of gas or liquid over the affected surface and is quantitated in terms of force (Dynes) per unit area (Box 1).

One of the most instructive exemplars of the interaction between drug action and shear stress is provided by the discovery of excess cardiovascular mortality associated with the use of cyclooxygenase 2 (COX2)-selective inhibitors (coxibs). Two COX enzymes are known. COX1 is ubiquitously expressed at significant levels and produces precursors for the formation of prostaglandin E₂, prostacyclin (PGI₂), and thromboxane A₂ to achieve cytoprotective, anti-atherogenic, and hemostatic physiological functions, respectively. COX2 was discovered in tumor cells and has been shown to be strongly induced by particular cytokines, growth factors, and receptors for pathogen-associated molecular patterns (PAMPs) in the mammalian innate host defense system.

The basis of the anticipated safety profile of selective COX2 inhibitors was in part dependent on a misapprehension of the dependence of vascular endothelial PGI₂ production on COX1 activity. The anti-thrombotic actions of PGI₂ were well-established a decade before the 1990 discovery of COX2. The mechanisms of anti-thrombotic actions of low-dose aspirin were known to involve preserved endothelial PGI₂ production and diminished production by platelets of the platelet-activating vasoconstrictor, thromboxane A₂. In 1996, 2 years before the coxibs were approved by the USA FDA, work by Gimbrone and colleagues indicated that, under static conditions and with the application of turbulent flow, cultured endothelial cells expressed COX1, whereas when subject to laminar flow, COX2 expression was strongly induced and therefore became an important source of enzymatic activity producing precursor for transformation into PGI₂ [12]. This finding is significant for being one of the early observations to draw our attention to the impact of shear forces on gene expression and function. Perhaps more importantly, it highlighted the importance of screening drug actions *in vitro* in settings that are more physiological with regard to flows and forces. The coxibs may compromise endothelial PGI₂ production, particularly in regions of high wall shear stress, which are also known to be sites of higher likelihood for rupture of atherosclerotic lesions [13]. More recent commentary on the basis of the cardiovascular risk posed by the coxib drug class has suggested that the mechanism may be multifaceted, involving macrophage and other sources of COX2 activity, in addition to the endothelium [14]. Hypertension, a pro-thrombotic state, and loss of protection from the preconditioning that follows intermittent episodes of ischemia, are each considered alongside endothelial COX2 expression as potential contributors to excess cardiovascular morbidity and mortality in patients treated with coxibs [15]. Evaluation of coxibs in endothelium subjected to appropriate shear forces may have alerted developers of this drug class to an otherwise unappreciated risk posed to cardiovascular safety. Moreover, because growth factors and cytokines induce COX2 [16], the soluble environment of the assay system is also a critical consideration. Regardless of the precise reasons for coxib toxicity, biomechanically accurate screening paradigms are evidently important for safety evaluation.

Shear forces play a key role in determining the pharmacology of anti-platelet agents. Examination of the role of integrins under static and shear stress conditions indicates that shear is able to alter the avidity of integrins not only for their binding partner but also for some small-molecule ligands that inhibit their activation [17]. The impact of inhibitors of the phosphoinositide 3-kinases (PI3Ks) are also sensitive to whether evaluation takes place under static or shear-stressed conditions, with implications for drug screening approaches [18]. Specifically, the role of the PI3K β isoform is most evident under the high shear stress where it contributes to the signaling regulating the transmission of force from the actin cytoskeleton of the activated platelet through the $\alpha_2\beta_3$ platelet integrin to the clot fibrin [19].

Force, Stress, Strain, and Stiffness

In most organs, smooth muscle functions under an environment of constant fluctuation of stress and strain. Control of the organ function can be achieved by regulating the intrinsic forces generated by the muscle. Conversely, the behavior of the muscle can be modified by extrinsic forces imposed on the muscle. Both the intrinsic and extrinsic forces lead to changes in the stresses and strains within the smooth muscle, altering its stiffness properties (see Box 1 for a primer on tissue/cell mechanics). Studies of the pharmacology of smooth muscle have conventionally been conducted under static conditions, in which the response to an intervention is usually the isometric force developed by the muscle. The inadequacy of this approach becomes clear when the responses of airway smooth muscle to agonist stimulation under static and dynamic conditions are compared. The dynamic loading experienced by airway smooth muscle in a breathing lung greatly attenuates the contractile responsiveness of the muscle [20,21]. Similar conclusions can be made for other smooth muscle, such as arterial smooth muscle under pulsatile pressure [22]. More importantly for understanding the pathophysiology of asthma, it appears that the inability of asthmatic airway smooth muscle to relax in response to mechanical perturbation may be the cause of airway hyper-responsiveness [23]. Impairment of airway distensibility may be associated with the lack of bronchodilatation in asthmatic airways under oscillatory strain [24]. Conversely, in healthy individuals, prohibition of deep inspiration leads to airway hyper-responsiveness [23], but more recent investigations suggest that the maximum response rather than sensitivity is increased [25]. These observations highlight airway stiffness, including airway smooth muscle stiffness, as potential targets for asthma therapy [26,27]. Force and stiffness development in airway smooth muscle appear to be regulated through separate signal pathways [28,29]. A recent study showed that fibroblast growth factor 2 (FGF2) reduces the transforming growth factor (TGF)- β -stimulated increase in stiffness of cultured airway smooth muscle cells [30], demonstrating the possibility of developing a new class of anti-asthma drugs that specifically targets smooth muscle stiffness.

Tensile Forces

Tensile stiffness of a muscle does not manifest itself until the muscle is stretched via tensile forces. To study any drug effect on muscle stiffness it is therefore necessary to apply the mechano-pharmacological approach. A recent study examining the combined effect of oscillatory strain and isoprenaline in dilating carbachol-constricted bronchial segments has found a synergy between the mechanical and pharmacological bronchodilators [31]. A

conventional pharmacological or purely static mechanical approach would have yielded smaller bronchodilator effects, suggesting that neither stimulus was effective. With increasing understanding of how smooth muscle contracts, we are now able to separate different phases of smooth muscle contraction regulated by different signaling pathways. In airway smooth muscle, force maintenance during the sustained phase of contraction is particularly sensitive to RHO kinase inhibitors. Synergy in reducing the ability of the muscle to maintain force becomes apparent when oscillatory strain is applied to the muscle in the presence of a RHO kinase inhibitor [32]. These examples underline the importance of applying mechanopharmacological approaches in identifying new drugs to target the range of contributions to asthma. In the context of fixed airway obstruction in asthmatics treated with optimal doses of inhaled glucocorticoids to treat inflammation, and with β_2 -adrenoceptor agonists to relieve the bronchospasm, there may be a limitation on the efficacy of the β_2 -adrenoceptor agonist in airway smooth muscle that has assumed a more-rigid state. Alternative targets to the β_2 -adrenoceptor may need to be evaluated in airways that are appropriately mechanically conditioned to reflect this particular unmet need in severe asthma.

Compressive Forces

The mechanotransduction paradigm of asthma was proposed following observations in an *in vitro* compressive system that mimics the estimated maximal compressive force exerted on airway epithelial cells during bronchoconstriction. This system has been used to show the recapitulation of various remodeling events as detected in the asthmatic airways [33–36].

While normal breathing imposes cyclic compressive stress at 3 cm H₂O of pressure on the airway epithelium, bronchospasm in asthma imposes static compressive stress at 25–30 cm H₂O pressure. Application of compressive stress reduces the lateral interstitial volume, thereby recapitulating the folded and compressed epithelium in narrowed airways [34]. Compressive stress cues mechanotransduction signals in airway epithelial cells via the activation of epidermal growth factor receptor. During compressive stress, epithelial cells release mediators that induce proliferation and the production of collagens types 1 and 3 from co-cultured fibroblasts [37]. In air–liquid interface cultures of airway epithelium, intermittent, repeated compressive stresses cause goblet cell hyperplasia in well-differentiated normal human bronchial epithelial (HBE) cells [38]. Moreover, compressive stress induces the release of inflammatory and angiogenic mediators, such as tissue factor and YKL-40 (also known as chitinase 3-like 1, CHI3L1) from HBE cells via protein kinase C (PKC) and extracellular signal-regulated kinase (ERK)-dependent pathways [39–40]. These studies using an *in vitro* compressive system suggest that, even in the absence of inflammatory cells, compressive mechanical stress imposed on airway epithelium activates mechanotransduction pathways that participate in airway remodeling of asthma. With an appreciation of previous *in vitro* studies, Grainge *et al.* reported results from a groundbreaking study in mild asthmatics showing that repeated challenges with a bronchoconstricting agent, methacholine, induce two major remodeling events – goblet cell hyperplasia and increased type 3 collagen deposition – in the absence of infiltration of inflammatory cells [41]. Pretreatment with a bronchodilator, albuterol, prevented the remodeling events induced by methacholine, thereby implicating mechanical compression

rather than other pharmacological effects of muscarinic receptor activation. Thus, compressive stress may accelerate the progression of remodeling in individuals with pre-existing conditions [42]. Persistent relaxation of the airways by long-acting β_2 -adrenoceptor agonists would be expected to offset these stimuli to remodeling, but this has yet to be convincingly demonstrated.

In connection with physical behaviors of cells, the asthmatic airway epithelium exhibits difference in the jamming transition. Like coffee beans in a chute, cells can become jammed or cells can flow [43,44]. When primary HBE cells are cultured from normal donors, they are initially unjammed, but when cells are differentiated and mature, they eventually become jammed [36]. However, when cells are cultured from asthmatic donors, the transition from the unjammed state to the jammed state is significantly delayed. Furthermore, the jammed state or the normal transition toward the jammed state can be disturbed by external stimuli or disease conditions. Compressive stress provokes the transition from the jammed state back to the unjammed state. These findings suggest that cell jamming can be a novel concept in understanding the role of the airway epithelium in asthma [45].

Although the impacts of mechanotransduction on the inflammatory response have not been extensively explored, a recent fascinating study indicates that elasticity influences the innate host defense functions of macrophages and that, conversely, both PAMPs (e.g., lipopolysaccharide, LPS) and cytokines, including interferon γ (IFN- γ), modulate macrophage elasticity [46]. It is notable that a number of the extracellular factors elaborated in response to strain and compression, including type 1 collagen, IFN- γ , and TGF- β are able to induce glucocorticoid resistance [47–49].

The Mechanical Environment of the Cell

A large number of studies have shown that mechanical interactions between cells and the extracellular matrix (ECM) play a fundamental role in biological processes such as migration, growth, and morphogenesis. Cellular responses to mechanical forces are highly complex. The mechanical environment may be viewed as a combination of ‘outside-in’ and ‘inside-out’ forces. When external forces are applied to tissue, these forces are transferred from the ECM to the cell, propagating from the outside into the cell (‘outside-in’). However, the cell also generates forces within itself, affecting its overall deformability and stiffness. These ‘inside-out’ forces are also often referred to as the cellular traction force. The forces applied to the cell and the traction forces generated by the cell are closely linked via a feedback loop. Growing cells on hard or soft substrates could increase or decrease cellular stiffness and traction force, respectively, with the cell responding constantly to its external microenvironment [50]. This feedback loop has generated wide interest in the research community, most strikingly in the area of stem cell biology. Pivotal advances in stem cell differentiation technology have been built on the finding that the biomechanical environment of stem cells contributes crucially to the nature of the niche that determines the fate of cellular differentiation [51]. Researchers are now able to tune substrate or ECM stiffness to guide differentiation [52]. Pharmacological manipulation of cellular mechanics using agents that impact on the cytoskeleton may offer a promising approach to altering the behavior of endogenous cell stem cells to effect repair. Agents that target central structures in the

cytoskeleton are usually cytotoxic. However, prospects for selective, safe and tolerable agents are emerging from an improved understanding of the molecular basis of mechanosensing [53]. In addition, pharmacological or genetic manipulation of autologous and allogeneic stem cell phenotype may extend the utility of stem cells as treatments.

The 2D or 3D environment of the cellular system has profound impacts on cellular behavior, some of which can be ascribed to changes in the mechanical microenvironment. Thus, the tensile, compression and shear forces experienced by cells within the 3D environment, together with spatial heterogeneity, engender more differentiation of gene expression and cellular phenotype. In cell culture models championed by Mina Bissell, tumor spheroids comprising epithelial cultures are produced in a low-adhesion environment, either in a hanging droplet or in low-adhesive plastic culture dishes, usually with some ECM components in solution to facilitate the agglomeration of the cell mass into a sphere. The size of the spheroid is limited to avoid hypoxia due to oxygen diffusion limitation. There are marked differences in epithelial monolayer cultures and 3D spheroids in respect to gene expression [54-55], activity of chemotherapy [56] and mechanisms of cell migration and invasion. These observations have been taken beyond the tumor environment to virtually all cell types in developing 3D organ-on-a-chip models [57]. Moreover, the use of 3D culture systems allows the identification of more relevant biomarkers [58], an increasingly crucial tool in drug discovery and development. The pathophysiological mechanical environment of the tumor can be mimicked in spheroids. Embedding these structures in distinct ECM environments facilitates more relevant investigation of tumor cell invasion and migration [59], whereas the impacts of static and dynamic loadings in this setting are yet to be explored.

Virtually all lung diseases involve alteration in lung mechanics through disease-related cellular changes. The extent to which these cell-level changes are influenced by intrinsic (age, sex, genetic background) and/or extrinsic (exposures to environmental stimuli) factors is a subject of much recent investigation. The example of adult respiratory distress syndrome (ARDS), a lethal disease endemic to intensive care units worldwide, is instructive. Mechanical ventilation was established as a treatment soon after ARDS was first described [60]. Subsequently, ventilation volume guidelines were refined in response to the finding that low levels of ventilator-imposed stretch are life-saving, whereas higher tidal volumes associated with greater stretch exacerbate lung injury [61]. In common with other causes of ARDS, increased plasma leakage via the compromised microvascular endothelial cell (EC) barrier is the major pathological outcome with ventilator-associated lung injury (VALI). Increased plasma leak is largely attributable to the impact of the large-amplitude stretch on EC intercellular forces, signaling pathways, cytoskeletal components, and cell-cell and cell-substrate adhesions [62-63]. Stretch-induced injury may be elicited mechanically or be secondary to inflammatory processes and/or mediators acting on the EC cytoskeleton. Regardless, targeting mechanotransduction pathways within the EC has emerged as a dominant therapeutic strategy in ARDS [64-65]. Key amongst these targets are myosin light-chain kinase, small GTPase RHOA, sphingosine-1-phosphate, RHO-specific guanosine nucleotide exchange factor, and protein kinases, amongst others [62-65]. In this connection, Grigoryev *et al.* examined EC-specific gene expression in human pulmonary microvascular endothelial cells exposed to high levels of cyclic mechanical stretch [66]. They identified

several gene variants that confer risk for VALI, including nicotinamide phosphoribosyltransferase (*NAMPT*) [67] and growth arrest DNA damage inducible 45α (*GADD45A*) [68], each of which is currently being pursued as a novel therapeutic target. Taken together, these studies highlight the importance of using cell mechanics to probe gene–environment interactions for drug discovery.

This emerging approach to gene–environment interactions is ideally exemplified by the use of epithelial organoids of intestinal origin to assess cystic fibrosis transmembrane conductance regulator (CFTR) phenotypes in patients with cystic fibrosis to ascertain their sensitivity to newly developed CFTR enhancers [69]. Misfolding or deficiency of expression of CFTR results in thickened mucus on epithelial surfaces, causing nutritional and respiratory problems. The biopsy-derived epithelia from CF patients are formed into a spheroid that is suspended in cell culture media. The structure forms tight junctions that serve to seal the internal extracellular compartment on the basolateral aspect of the epithelial from the external bathing fluid. As the CFTR channel activity increases, the spheroid swells, producing a very simple optical endpoint in an assay that personalizes drug screening. This latter model can be considered to be mechanically active. Its output is not dependent on mechanosensing, but simply on swelling caused by fluid transport.

Selected Bioassays for Use in Mechanopharmacology

Two main principles for mechanopharmacological bioassays are that the input dynamic environment is biomechanically similar to that of the cells in the target organ, and that there is a quantitative output measure of the biomechanical activity of the target structure.

Substrate Stiffness

Substrate stiffness has a pervasive influence on cell biology because it modulates cell adhesion, spreading, deformation, and migration, as well as contraction, growth, differentiation, and apoptosis [50–70–73]. For example, Engler *et al.* [72] demonstrated that lineage specification in naïve mesenchymal stem cells is intimately linked to stiffness of the substrate upon which the cells are adherent; soft substrates that mimic brain-like stiffness promote neurogenesis, while stiffer substrates that mimic muscle-like and bone-like stiffness promote myogenesis and osteogenesis, respectively. Substrate stiffness is also of great relevance to the pathogenesis of a wide range of diseases including diabetes, cancer, pulmonary fibrosis, hypertension, and acute lung injury. Nevertheless, standard cell-culture platforms in high-throughput biology have lacked the ability to incorporate soft-substrates in multiwell preparations. To address that gap, Mih *et al.* developed a method to miniaturize polyacrylamide substrates in 96-well or 384-well plates [74]. The stiffness of the substrate is tunable from ~0.5 kPa to 90 kPa, spanning the known (patho)physiological range. The platform is compatible with standard imaging systems and opens new opportunities to investigate cell spreading, division, growth, migration, and apoptosis in a biomechanically relevant microenvironment, using high-throughput platforms. This higher-throughput system is currently limited to a 2D environment.

Substrate Stretch

Mechano-screening is at an advanced stage of development for shear and stretch. Lung-on-a-chip technology incorporating an air liquid interface with epithelium apposed to vascular endothelial cells has been used to emulate the stretching caused by breathing, coupled with shear caused by fluid flow [75]. These chips were used to establish the potential of TRPV4 (transient receptor potential cation channel V4) inhibitors in treating vascular injury leading to pulmonary edema in response to interleukin 2 [76], an immunostimulant used to treat some solid tumors. This work has been translated, with successful preclinical animal studies showing that orally active TRPV4 channel inhibitors prevent pulmonary edema associated with heart failure [77]. Interest in the potential to modulate TRPV4 in respiratory disease is growing with its importance in mechanosensing being more widely appreciated [78], and recent evidence suggesting a role in pulmonary fibrosis [79].

Commercial application of devices that emulate (patho)physiological shear forces characteristically experienced by the vascular endothelium has now been achieved, although further evaluation is required to fully assess any improvements in predictive value. Devices enabling cyclical stretch such as the Flexcell™ have been available since the 1990s. Recent advances in micro-scaled devices that enable physiological frequency and amplitudes of stretch to be applied to organoids, so-called organ-on-a-chip devices, are at the threshold of widespread commercial use. These developments have prompted interest from the US National Centre on Advancing Translational Sciences (NCATS) to fund the development of models and to initiate conversations between academics, Pharma/Biotech and regulators, including a program funding 'Tissue Chip Projects' (<https://ncats.nih.gov/tissuechip>), predicating 'disease-on-a-chip'.

Cellular Properties in Suspended Cells

A better understanding of the relationship between cell mechanical changes and disease outcomes has also allowed us to exploit new methods for drug mechano-screening. For example, the micropipette aspiration technique [80] has been used to characterize changes in whole-cell mechanical properties due to drugs or diseases. A controlled suction pressure is applied through to the surface of a single cell using a micropipette. The pressure is finely regulated, and real-time images of the aspirated cell or cell elongation into the micropipette are recorded as suction pressure increases. Assuming the cell to be a homogeneous, isotropic, linear elastic, and incompressible half-space medium, the whole cell stiffness and the viscoelastic properties can be calculated from the applied pressure and the corresponding cell elongation [80]. Airway smooth muscle (ASM) cell exposure to TGF- β increases ASM cell stiffness, whereas basic fibroblast growth factor (bFGF) prevents this increase in stiffness [30], as measured by micropipette aspiration (Figure 1). The micropipette aspiration technique has been used to evaluate the effects of antimetabolic microtubule-targeting agents on cancer cells, correlating increased whole-cell stiffness and viscoelastic properties to microtubule/microfilament content in the cell cytoskeletal network [81]. Treatment of tumor cells with anti-mitotic agents reduced the elevated cell stiffness. Each of these studies highlights the potential of the intrinsic cellular mechanical properties, such as stiffness, to serve as a biomarker of disease activity and of therapeutic activity of interventions. The potential for high-throughput screening could also be seen in some lab-

on-chip devices combining micropipette aspiration technique with microfluidics for mechano-phenotyping applications. Lee *et al.* described the combined polydimethylsiloxane (PDMS) chip fabricated using a soft lithography technique [82]. The chip consisted of a filtering unit allowing only single cells (as opposed to cell clumps) to enter 16 micro-channels or arrays. Each array incorporated four aspiration chambers on each side, allowing single cells to be aspirated in a high-throughput manner. These studies confirmed earlier observations suggesting that metastatic tumor cells have a lower stiffness, enabling greater deformability to transmigrate vascular barriers to metastasis. Another high-throughput approach in suspended cells involves applying hydrodynamic stretching on single cells. Dudani *et al.* described a process termed ‘hydropipetting’, wherein a cell in suspension is moved at high speed in microfluidic channels and is deformed by hydrodynamic forces generated when the cell flows past perpendicular branching channels that generate a cross-flow, causing a pinching effect on the cell [83]. Unlike the devices based on micropipette aspiration, the cells are not in contact with the channel walls. Speeds of up to 65000 cells/second are possible with ‘hydro-pipetting’. Other approaches in suspended cells include varied methods for screening cell deformability in the context of malaria [84], cancer [85], and malignant pleural effusions [86]. Analyses of cells in suspension provide access to fluidics technologies, but if the tissue of origin is a solid organ then the disruption of isolation and lack of ECM attachment comprises a perturbation of normal cell physiology, thereby potentially limiting the applicability of the data.

Cellular Properties in Adherent Cells

Limited information is provided by cell stiffness measurements in the suspended cells because this setting does not provide quantitative data on the interactions between the cell and its microenvironment or ECM. The main cellular structural element is the cytoskeleton, which comprises an array of protein filaments that provide the mechanical connections from the cell membrane to the nucleus. The cytoskeleton is anchored to the ECM, and less commonly to adjacent cells, via discrete points known as focal adhesions (FA) that serve as the conduit for mechanosignaling. The FA sense external mechanical forces, as well acting to balance the internal forces produced with the cytoskeleton [87]. A common approach to measuring forces transmitted at the FA is the technique of traction force microscopy. One embodiment of traction force microscopy uses culture of cells on micro-pillars [88]. PDMS micropillars are fabricated using a silicon mold etched by standard micromachining techniques (Figure 2). The micropillar array is then calibrated using a micromanipulator to obtain its spring constant. The cells placed on top of the pillars attach to the individual pillars via the FA. The cell traction is calculated by the amount of deflection of the individual pillars. Another embodiment of traction force microscopy uses culture of cells upon deformable substrates. Impregnated in the substrates are fluorescent microbeads; by tracking microbead displacements cell-exerted substrate deformations are calculated. Based on substrate deformation and with knowledge of substrate stiffness, the cell traction forces can be obtained [70–72;89–91].

The aforementioned technologies are largely limited to low-throughput settings, and are therefore impractical for use in screening for agents targeted to mechanisms subserving cell traction. Instead, available drug screening technologies use varied biochemical (e.g.,

cytoplasmic calcium levels) or structural surrogates (e.g., expression levels of filamentous actin) for investigation of traction. These approaches do not adequately deal with false positives or false negatives. To address this gap, Park *et al.* recently miniaturized the setting of traction force microscopy to 96-well plates and developed a new medium- to high-throughput method called contractile force screening (CFS) [11]. CFS is likely to facilitate drug discovery and drug repurposing in circumstances in which modulation of cell traction is the logical therapeutic target, including but not limited to asthma, chronic obstructive pulmonary disease (COPD), vascular and cardiac disease, pulmonary arterial hypertension, glaucoma, kidney disease, and cancer.

Another biomechanical screening approach in the adherent cell is the magnetic twisting cytometry, a commonly used technique to screen for impacts on cell stiffness [92–94]. During magnetic twisting cytometry measurements, ferromagnetic beads (4.5 μm in diameter) are tightly anchored to the cell cytoskeleton and oscillated using a known magnetic field (5–75 Gauss). From the ratio of the imposed bead torque to the resulting bead motion, the cell stiffness can be experimentally determined.

Cellular Properties in 3D

Pseudo-3D techniques have been attempted by growing cells between micropillars [95], or by hanging cells using bent cantilever beams [96]. However, these methods do not fully mimic the physiological nature of cells embedded in 3D, particularly because the ensemble responses of multicellular structures are not accounted for in these assays. To overcome this limitation, cell aggregates or cell spheroid preparations have been proposed. Spheroid stiffness has been measured using the micropipette aspiration techniques [97]. Nevertheless, significant challenges remain in handling spheroids under high-throughput conditions owing to their size and their potential to disintegrate. Traction force measurements in spheroids have also been attempted using large aspect ratio micropillars [98]. Nonetheless, high-throughput systems based on micropillar or cantilever principles have been extremely difficult to construct. Instead, the current state-of-the-art in 3D traction force microscopy is to culture a population of cells in a 3D collagen gel matrix embedded with fluorescent beads. The forces generated by the cells create a pre-stress condition on the gel. Following the experiment, the cell cytoskeleton is destroyed using drugs causing the cell to detach from the gel matrix, releasing the overall pre-stress on the gel, which is tracked by measuring the fluorescent bead displacements [99]. However, challenges remain in relating the overall pre-stress on the gel to the traction force contributions of individual cells. Computational techniques, such as finite element (FE) analysis, have been used to predict the individual cell traction force using information gathered from the overall displacement of beads within the gel [100]. 2D traction force microscopy offers significant potential for high-throughput drug screening, but further development is needed for 3D screening with significant throughput. The lung slice may be subjected to traction force microscopy through similar approaches to those used in cell monolayer experiments, and has the advantage of maintaining spatial geometry and cell heterogeneity [101]. Particle-tracking microrheology may offer an approach to these challenges [102].

Concluding Remarks

The emergence of methodologies to culture cells in microenvironments that better reflect the mechanical, soluble, and insoluble (ECM) environment of the diseased tissue bearing the drug target creates an impetus to use such models for drug screening. Efforts to increase the throughput of such methodologies, while maintaining cells in a 3D setting with appropriate mechanical loading characteristics, need to be complemented by improvements in the patterns of drug and mediator exposure that are also aligned to the patterns prevailing at the drug target in the diseased tissue. A focus on these pharmacodynamic/pharmacokinetic relationships using human cell-derived 3D organoids appears likely to improve their predictive value for target identification and drug screening (see Outstanding Questions). We have not covered exciting developments in what might be regarded as mechano-pharmaceutics, in which nanotechnology is being applied to pharmaceutical formulation to exploit mechanical forces that cause localized or selective liberation of drugs from their nanoparticle delivery systems [103].

Our view is that there is a need for a subdiscipline of mechanopharmacology, which will serve as a focus for activities that are highly interdisciplinary. The closest term to our proposal is biomechanopharmacology [7], but this descriptor has not achieved widespread acceptance, perhaps because it is not aligned with similar terms, including mechanomedicine, mechanotherapy [104], mechanotherapeutics [103], or mechanobiology. Mechanopharmacology has been used previously to describe the study of the mechanics of individual proteins [6,105]; our proposed usage covers a wider conceptual field. The discussion of best-practice in models, scope of studies, and the state of the art, as well as of the development of a repository for accepted principles, needs to be concentrated rather than distributed among a large number of diverse professional/learned societies, as is presently the case. The drive to establish this interdisciplinary derives from the desire to improve the relevance of target discovery and screening models to tissues *in situ* and to human disease, with the ultimate hope of better prediction of efficacy in the clinic.

Acknowledgments

We thank Fernando Guzman for the image used in Figure 1. The work of the authors that is discussed in this manuscript was supported by grants from the National Health and Medical Research Council (105966; 1045372), a Dyason Fellowship, and a Global Mobility Strategic Enhancement grant (University of Melbourne).

References

1. Cook D, et al. Lessons learned from the fate of Astra-Zeneca's drug pipeline: a five-dimensional framework. *Nat Rev Drug Discov.* 2014; 13:419–431. [PubMed: 24833294]
2. Sukharev S, Sachs F. Molecular force transduction by ion channels: diversity and unifying principles. *J Cell Sci.* 2012; 125:3075–3083. [PubMed: 22797911]
3. Ranade SS, et al. Mechanically activated ion channels. *Neuron.* 2015; 87:1162–1179. [PubMed: 26402601]
4. Schiller HB, Fassler R. Mechanosensitivity and compositional dynamics of cell-matrix adhesions. *EMBO Rep.* 2013; 14:509–519. [PubMed: 23681438]
5. Yan J, et al. Talin-dependent mechanosensitivity of cell focal adhesions. *Cell Mol Bioeng.* 2015; 8:151–159. [PubMed: 26097520]

6. Yao M, et al. Mechanical activation of vinculin binding to talin locks talin in an unfolded conformation. *Sci Rep.* 2014; 4:4610. [PubMed: 24714394]
7. Liao F, et al. Biomechanopharmacology: a new borderline discipline. *Trends Pharmacol Sci.* 2006; 27:287–289. [PubMed: 16678914]
8. Huang C, et al. Mechanotherapy: revisiting physical therapy and recruiting mechanobiology for a new era in medicine. *Trends Mol Med.* 2013; 19:555–564. [PubMed: 23790684]
9. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. *Integr Biol.* 2013; 5:1119–1129.
10. Huh D, et al. Microfabrication of human organs-on-chips. *Nat Protoc.* 2013; 8:2135–2157. [PubMed: 24113786]
11. Park CY, et al. High-throughput screening for modulators of cellular contractile force. *Integr Biol.* 2015; 7:1318–1324.
12. Topper JN, et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclo-oxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proc Natl Acad Sci USA.* 1996; 93:10417–10422. [PubMed: 8816815]
13. Dolan JM, et al. High wall shear stress and spatial gradients in vascular pathology: a review. *Ann Biomed Eng.* 2013; 41:1411–1427. [PubMed: 23229281]
14. Marnett LJ. The COXIB experience: a look in the rearview mirror. *Annu Rev Pharmacol Toxicol.* 2009; 49:265–290. [PubMed: 18851701]
15. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. *Circulation.* 2014; 129:907–916. [PubMed: 24566065]
16. Mitchell JA, et al. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. *FASEB J.* 2006; 20:2468–2475. [PubMed: 17142796]
17. Nissinen L, et al. Novel alpha2beta1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation. *J Biol Chem.* 2012; 287:44694–44702. [PubMed: 23132859]
18. Jackson SP, Schoenwaelder SM. Antithrombotic phosphoinositide 3-kinase beta inhibitors in humans: a ‘shear’ delight! *J Thromb Haemost.* 2012; 10:2123–2126. [PubMed: 22943292]
19. Schoenwaelder SM, et al. Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. *J Biol Chem.* 2010; 285:2886–2896. [PubMed: 19940148]
20. Moore BJ, et al. The effect of deep inspiration on methacholine dose-response curves in normal subjects. *Am J Respir Crit Care Med.* 1997; 156:1278–1281. [PubMed: 9351635]
21. Lavoie TL, et al. Dilatation of the constricted human airway by tidal expansion of lung parenchyma. *Am J Respir Crit Care Med.* 2012; 186:225–232. [PubMed: 22679010]
22. Seow CY. Response of arterial smooth muscle to length perturbation. *J Appl Physiol.* 1985; 89:2065–2072. [PubMed: 11053363]
23. Skloot G, et al. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. *J Clin Invest.* 1995; 96:2393–2403. [PubMed: 7593627]
24. Pyrgos G, et al. Bronchodilation response to deep inspirations in asthma is dependent on airway distensibility and air trapping. *J Appl Physiol.* 1985; 110:472–479. [PubMed: 21071596]
25. Chapman DG, et al. Avoiding deep inspirations increases the maximal response to methacholine without altering sensitivity in non-asthmatics. *Respir Physiol Neurobiol.* 2010; 173:157–163. [PubMed: 20688195]
26. Seow CY. Passive stiffness of airway smooth muscle: the next target for improving airway distensibility and treatment for asthma? *Pulm Pharmacol Ther.* 2013; 26:37–41. [PubMed: 22776694]
27. An SS, et al. A novel small molecule target in human airway smooth muscle for potential treatment of obstructive lung diseases: a staged high-throughput biophysical screening. *Respir Res.* 2011; 12:8. [PubMed: 21232113]

28. Raqeeb A, et al. Regulatable stiffness in relaxed airway smooth muscle: a target for asthma treatment? *J Appl Physiol.* 1985; 112:337–346. [PubMed: 21998272]
29. Lan B, et al. Rho-kinase mediated cytoskeletal stiffness in skinned smooth muscle. *J Appl Physiol.* 1985; 115:1540–1552. [PubMed: 24072407]
30. Schuliga M, et al. Transforming growth factor-beta-induced differentiation of airway smooth muscle cells is inhibited by fibroblast growth factor-2. *Am J Respir Cell Mol Biol.* 2013; 48:346–353. [PubMed: 23239497]
31. Ansell TK, et al. Pharmacological bronchodilation is partially mediated by reduced airway wall stiffness. *Br J Pharmacol.* 2014; 171:4376–4384. [PubMed: 24846164]
32. Lan B, et al. Force maintenance and myosin filament assembly regulated by Rho-kinase in airway smooth muscle. *Am J Physiol Lung Cell Mol Physiol.* 2015; 308:L1–L10. [PubMed: 25305246]
33. Chu EK, et al. Bronchial epithelial compression regulates epidermal growth factor receptor family ligand expression in an autocrine manner. *Am J Respir Cell Mol Biol.* 2005; 32:373–380. [PubMed: 15705969]
34. Tschumperlin DJ, et al. Mechanotransduction through growth-factor shedding into the extracellular space. *Nature.* 2004; 429:83–86. [PubMed: 15103386]
35. Park JA, et al. Putting the 2squeeze on airway epithelia. *Physiology.* 2015; 30:293–303. [PubMed: 26136543]
36. Park JA, et al. Unjamming and cell shape in the asthmatic airway epithelium. *Nat Mater.* 2015; 14:1040–1048. [PubMed: 26237129]
37. Swartz MA, et al. Mechanical stress is communicated between different cell types to elicit matrix remodeling. *Proc Natl Acad Sci USA.* 2001; 98:6180–6185. [PubMed: 11353845]
38. Park JA, Tschumperlin DJ. Chronic intermittent mechanical stress increases MUC5AC protein expression. *Am J Respir Cell Mol Biol.* 2009; 41:459–466. [PubMed: 19168703]
39. Park JA, et al. Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. *J Allergy Clin Immunol.* 2012; 130:1375–1383. [PubMed: 22828416]
40. Park JA, et al. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. *J Biol Chem.* 2010; 285:29817–29825. [PubMed: 20650887]
41. Grainge CL, et al. Effect of bronchoconstriction on airway remodeling in asthma. *N Engl J Med.* 2011; 364:2006–2015. [PubMed: 21612469]
42. Grainge C, et al. Asthmatic and normal respiratory epithelial cells respond differently to mechanical apical stress. *Am J Respir Crit Care Med.* 2014; 190:477–480. [PubMed: 25127309]
43. Haeger A, et al. Collective cell migration: guidance principles and hierarchies. *Trends Cell Biol.* 2015; 25:556–566. [PubMed: 26137890]
44. Sadati M, et al. Collective migration and cell jamming. *Differentiation.* 2013; 86:121–125. [PubMed: 23791490]
45. Swartz MA. Tissue mechanics: Cell jam. *Nat Mater.* 2015; 14:970–971. [PubMed: 26395940]
46. Patel NR, et al. Cell elasticity determines macrophage function. *PLoS ONE.* 2012; 7:e41024. [PubMed: 23028423]
47. Keenan CR, et al. Bronchial epithelial cells are rendered insensitive to glucocorticoid transactivation by transforming growth factor-beta1. *Respir Res.* 2012; 15:55. [PubMed: 24886104]
48. Salem S, et al. Transforming growth factor-beta impairs glucocorticoid activity in the A549 lung adenocarcinoma cell line. *Br J Pharmacol.* 2012; 166:2036–2048. [PubMed: 22300324]
49. Keenan CR, et al. Heterogeneity in mechanisms influencing glucocorticoid sensitivity: the need for a systems biology approach to treatment of glucocorticoid-resistant inflammation. *Pharmacol Ther.* 2015; 150:81–93. [PubMed: 25596317]
50. Discher D, et al. Biomechanics: cell research and applications for the next decade. *Ann Biomed Eng.* 2009; 37:847–859. [PubMed: 19259817]
51. Jacot JG, et al. Mechanobiology of cardiomyocyte development. *J Biomech.* 2010; 43:93–98. [PubMed: 19819458]

52. Viswanathan P, et al. 3D surface topology guides stem cell adhesion and differentiation. *Biomaterials*. 2015; 52:140–147. [PubMed: 25818420]
53. Low BC, et al. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. *FEBS Lett*. 2014; 588:2663–2670. [PubMed: 24747426]
54. Spencer VA, et al. Gene expression in the third dimension: the ECM–nucleus connection. *J Mammary Gland Biol Neoplasia*. 2010; 15:65–71. [PubMed: 20107877]
55. Mammoto A, et al. Mechanosensitive mechanisms in transcriptional regulation. *J Cell Sci*. 2012; 125:3061–3073. [PubMed: 22797927]
56. Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. *Drug Resist Updat*. 2012; 15:39–49. [PubMed: 22335920]
57. Ingber DE, et al. Tensegrity, cellular biophysics, and the mechanics of living systems. *Rep Prog Phys*. 2014; 77:046603. [PubMed: 24695087]
58. Weigelt B, et al. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. *Adv Drug Deliv Rev*. 2014:69–70. [PubMed: 25451857]
59. Vinci M, et al. Three-dimensional (3D) tumor spheroid invasion assay. *J Vis Exp*. 2015; 2015:e52686. [PubMed: 25993495]
60. Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. *Chest*. 1971; 60:233–239. [PubMed: 4937358]
61. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med*. 2000; 342:1301–1308. [PubMed: 10793162]
62. Birukova AA, et al. Endothelial permeability is controlled by spatially defined cytoskeletal mechanics: atomic force microscopy force mapping of pulmonary endothelial monolayer. *Nanomedicine*. 2009; 5:30–41. [PubMed: 18824415]
63. Frank JA, et al. Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs. *Am J Respir Crit Care Med*. 2002; 165:242–249. [PubMed: 11790662]
64. Garcia JG. Concepts in microvascular endothelial barrier regulation in health and disease. *Microvasc Res*. 2009; 77:1–3. [PubMed: 19232241]
65. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. *Physiol Rev*. 2006; 86:279–367. [PubMed: 16371600]
66. Grigoryev DN, et al. Orthologous gene-expression pro-filing in multi-species models: search for candidate genes. *Genome Biol*. 2004; 5:R34. [PubMed: 15128448]
67. Sun X, et al. Enhanced interaction between focal adhesion and adherens junction proteins: involvement in sphingosine 1-phosphate-induced endothelial barrier enhancement. *Microvasc Res*. 2009; 77:304–313. [PubMed: 19323978]
68. Meyer NJ, et al. GADD45a is a novel candidate gene in inflammatory lung injury via influences on Akt signaling. *FASEB J*. 2009; 23:1325–1337. [PubMed: 19124556]
69. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. *Science*. 2013; 340:1190–1194. [PubMed: 23744940]
70. Prager-Khoutorsky M, et al. Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing. *Nat Cell Biol*. 2011; 13:1457–1465. [PubMed: 22081092]
71. Krishnan R, et al. Substrate stiffening promotes endothelial monolayer disruption through enhanced physical forces. *Am J Physiol Cell Physiol*. 2011; 300:C146–C154. [PubMed: 20861463]
72. Engler AJ, et al. Matrix elasticity directs stem cell lineage specification. *Cell*. 2006; 126:677–689. [PubMed: 16923388]
73. Liu F, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. *J Cell Biol*. 2010; 190:693–706. [PubMed: 20733059]
74. Mih JD, et al. A multiwell platform for studying stiffness-dependent cell biology. *PLoS ONE*. 2011; 6:e19929. [PubMed: 21637769]

75. Huh D, et al. Reconstituting organ-level lung functions on a chip. *Science*. 2010; 328:1662–1668. [PubMed: 20576885]
76. Huh D, et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. *Sci Transl Med*. 2012; 4:159ra147.
77. Thorneloe KS, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. *Sci Transl Med*. 2012; 4:159ra148.
78. Hill-Eubanks DC, et al. Vascular TRP channels: performing under pressure and going with the flow. *Physiology*. 2014; 29:343–360. [PubMed: 25180264]
79. Rahaman SO, et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. *J Clin Invest*. 2014; 124:5225–5238. [PubMed: 25365224]
80. Hochmuth RM. Micropipette aspiration of living cells. *J Biomech*. 2000; 33:15–22. [PubMed: 10609514]
81. Seyedpour SM, et al. Effects of an antimitotic drug on mechanical behaviours of the cytoskeleton in distinct grades of colon cancer cells. *J Biomech*. 2015; 48:1172–1178. [PubMed: 25678199]
82. Lee LM, Liu AP. A microfluidic pipette array for mechanophenotyping of cancer cells and mechanical gating of mechanosensitive channels. *Lab Chip*. 2015; 15:264–373. [PubMed: 25361042]
83. Dudani JS, et al. Pinched-flow hydrodynamic stretching of single-cells. *Lab Chip*. 2013; 13:3728–3734. [PubMed: 23884381]
84. Mauritz JM, et al. Detection of Plasmodium falciparum-infected red blood cells by optical stretching. *J Biomed Opt*. 2010; 15:030517. [PubMed: 20615000]
85. Guck J, et al. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. *Biophys J*. 2005; 88:3689–3698. [PubMed: 15722433]
86. Tse HT, et al. Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping. *Sci Transl Med*. 2013; 5:212ra163.
87. Ingber DE. Tensegrity: the architectural basis of cellular mechanotransduction. *Annu Rev Physiol*. 1997; 59:575–599. [PubMed: 9074778]
88. Maeda E, et al. Cytoskeletal tension modulates MMP-1 gene expression from tenocytes on micropillar substrates. *J Biomech*. 2013; 46:991–997. [PubMed: 23415423]
89. Krishnan R, et al. Fluidization, resolidification, and reorientation of the endothelial cell in response to slow tidal stretches. *Am J Physiol Cell Physiol*. 2012; 303:C368–C375. [PubMed: 22700796]
90. Krishnan R, et al. Reinforcement versus fluidization in cytoskeletal mechanoresponsiveness. *PLoS ONE*. 2009; 4:e5486. [PubMed: 19424501]
91. An SS, et al. Do biophysical properties of the airway smooth muscle in culture predict airway hyperresponsiveness? *Am J Respir Cell Mol Biol*. 2006; 35:55–64. [PubMed: 16484685]
92. An SS, et al. TAS2R activation promotes airway smooth muscle relaxation despite beta(2)-adrenergic receptor tachyphylaxis. *Am J Physiol Lung Cell Mol Physiol*. 2012; 303:L304–L311. [PubMed: 22683571]
93. Zhou EH, et al. Mechanical responsiveness of the endothelial cell of Schlemm's canal: scope, variability and its potential role in controlling aqueous humour out flow. *J R Soc Interface*. 2011; 9:1144–1155. [PubMed: 22171066]
94. Coughlin MF, et al. Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential. *Clin Exp Metastasis*. 2013; 30:237–250. [PubMed: 22961212]
95. Ghibaudo M, et al. Mechanics of cell spreading within 3D-micropatterned environments. *Lab Chip*. 2011; 11:805–812. [PubMed: 21132213]
96. Marelli M, et al. Cell force measurements in 3D micro-fabricated environments based on compliant cantilevers. *Lab Chip*. 2014; 14:286–293. [PubMed: 24217771]
97. Guevorkian K, et al. Aspiration of biological viscoelastic drops. *Phys Rev Lett*. 2010; 104:218101. [PubMed: 20867138]
98. Aoun L, et al. Microdevice arrays of high aspect ratio poly (dimethylsiloxane) pillars for the investigation of multicellular tumour spheroid mechanical properties. *Lab Chip*. 2014; 14:2344–2353. [PubMed: 24836927]

99. Hall MS, et al. Toward single cell traction microscopy within 3D collagen matrices. *Exp Cell Res*. 2013; 319:2396–2408. [PubMed: 23806281]
100. Legant WR, et al. Multidimensional traction force microscopy reveals out-of-plane rotational moments about focal adhesions. *Proc Natl Acad Sci USA*. 2013; 110:881–886. [PubMed: 23277584]
101. Rosner SR, et al. Airway contractility in the precision-cut lung slice after cryopreservation. *Am J Respir Cell Mol Biol*. 2014; 50:876–881. [PubMed: 24313705]
102. Mak M, et al. Impact of dimensionality and network disruption on microrheology of cancer cells in 3D environments. *PLoS Comput Biol*. 2014; 10:e1003959. [PubMed: 25412385]
103. Korin N, et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. *Science*. 2012; 337:738–742. [PubMed: 22767894]
104. Ingber DE. Mechanobiology and diseases of mechanotransduction. *Ann Med*. 2003; 35:564–577. [PubMed: 14708967]
105. Suchyna TM, et al. Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers. *Nature*. 2004; 430:235–240. [PubMed: 15241420]
106. Treppe X, et al. Universal physical responses to stretch in the living cell. *Nature*. 2007; 447:592–595. [PubMed: 17538621]
107. Ehrlicher AJ, et al. Alpha-actinin binding kinetics modulate cellular dynamics and force generation. *Proc Natl Acad Sci USA*. 2015; 112:6619–6624. [PubMed: 25918384]
108. Lele T, et al. Methods for measuring rates of protein binding to insoluble scaffolds in living cells: histone H1–chromatin interactions. *J Cell Biochem*. 2006; 99:1334–1342. [PubMed: 16795044]
109. Tambe DT, et al. Collective cell guidance by cooperative intercellular forces. *Nat Mater*. 2011; 10:469–475. [PubMed: 21602808]
110. Treppe X, et al. Physical forces during collective cell migration. *Nat Phys*. 2009; 5:426–430.
111. Kim HJ, Ingber DE. Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. *Integr Biol*. 2013; 5:1130–1140.
112. du Roure O, et al. Force mapping in epithelial cell migration. *Proc Natl Acad Sci USA*. 2005; 102:2390–2395. [PubMed: 15695588]
113. Meyer CJ, et al. Mechanical control of cyclic AMP signalling and gene transcription through integrins. *Nat Cell Biol*. 2000; 2:666–668. [PubMed: 10980709]
114. Ingber DE, et al. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. *J Biomech*. 1995; 28:1471–1484. [PubMed: 8666587]
115. Chen CS, et al. Geometric control of cell life and death. *Science*. 1997; 276:1425–1428. [PubMed: 9162012]
116. Haase K, Pelling AE. Investigating cell mechanics with atomic force microscopy. *J R Soc Interface*. 2015; 12:20140970. [PubMed: 25589563]
117. Guo M, et al. Probing the stochastic, motor-driven properties of the cytoplasm using force spectrum microscopy. *Cell*. 2014; 158:822–832. [PubMed: 25126787]
118. Griffin MA, et al. Patterning, prestress, and peeling dynamics of myocytes. *Biophys J*. 2004; 86:1209–1222. [PubMed: 14747355]
119. Mann JM, et al. A silicone-based stretchable micropost array membrane for monitoring live-cell subcellular cytoskeletal response. *Lab Chip*. 2012; 12:731–740. [PubMed: 22193351]

Box 1**Cell Mechanics Made Easy**

Tension, compression, bending, and shear: there are four major loads that a cell, a tissue segment, and/or an organ must withstand. These loads are illustrated diagrammatically in Figure I. The loads can arise external to the cell as a result of fluid flow, stretch, and/or constriction, or arise internally within the cell via active force generation through the cellular contractile apparatus. An external force acting over an area may be applied as a tensile, compressive, bending, or shear stress. Such stress causes a local deformation (strain). The material properties of the tissue can be probed by establishing the stress/strain relationship.

Cell mechanics: this refers to any cellular process during which mechanical forces are generated, imparted, or sensed (Figure I). The underlying mechanical–biochemical interactions not only mediate physical and structural changes [90·106·107], but also promote cell adhesion [108], polarization [70], stem cell differentiation [72], locomotion [109–111], wound healing [112], gene expression [113], angiogenesis [114], and apoptosis [115]. Consequently, defects in cell or ECM mechanics, often caused by maladaptation or malfunction of cell and ECM proteins, have been implicated in the development of numerous diseases (see Table 1 for selected examples).

Traction: the local force per unit area that is imposed on the microenvironment by an adherent cell. Traction arises due to complex interactions between molecular motors, cytoskeletal filaments, and adhesion molecules within the cell, together with the microenvironment. Ensuing interactions are powered by three intracellular processes: ATP hydrolysis, actin polymerization, and cell–cell and cell–substrate adhesion assembly/disassembly.

Cell stiffness: in response to an external force, the extent to which a cell resists deformation is termed stiffness. To measure this property the external force can be imposed locally via a magnetic bead, a tweezer, a cantilever beam, an intracellular tracer particle, or a microneedle pulling on receptors (e.g., integrins) on the cell surface [116·117], or can be imposed globally via whole-cell aspiration [118] or stretch [90·106·119].

Figure I. Potential Biomechanical Impacts of Cell and Matrix Are Depicted

The terms are discussed in detail in the text. The cross-sectional area (A) of the cell is the usual orientation for the forces (F ; compression, contraction, load) to be applied, especially in smooth muscle bundles. The term F/A denotes the stress applied to or exerted by the cell when being compressed or contracting, respectively.

Trends

An argument is outlined for a new interdisciplinary: mechanopharmacology.

Examples of cellular biomechanics influences on drug action are described.

The relevance of matrix stiffness and of internal and external stresses to drug screening is discussed.

Methods for the biomechanical perturbation and analysis of single cells and organoids are reviewed.

Outstanding Questions

Will improvements in the cellular mechanics of evaluation and screening paradigms result in better prediction of efficacy?

Will disease-on-a-chip technology be widely adopted?

Will personalized drug screening becoming commonplace through the use of organoids from patient-derived cells (possibly reprogrammed through an induced pluripotent stem cell pathway to the relevant phenotype)?

Will the relationship between pharmacokinetics and pharmacodynamics be explored in subacute timeframes of days to weeks in lower-throughput settings to better predict drug efficacy in chronic disease?

Can a new interdisciplinary of mechano-pharmacology serve to accelerate progress in applying new insights in cellular mechanics to drug screening and evaluation?

Figure 1. Micropipette Aspiration of a Single Cell [30] or Cell Aggregate (Shown) Causes the Cellular Mass To Be Drawn into the Lumen of the Micropipette and Elongated in a Pressure-Dependent Manner

These aspiration experiments provide the data required for calculation of cell stiffness, which is related to the slope of the relationship between applied pressure and corresponding elongation.

Figure 2. Single-Cell Traction Force Measurements on Micropillars

The region of interest marked by the grey outline identifies an area corresponding to a portion of a single cell, which is exerting traction on the underlying pillars. The direction and the extent of the deflection of the pillar are used to calculate a traction vector (blue arrow).

Table 1

Defects in Cell Mechanics (C) and ECM Mechanics (E) Are at the Forefront of a Wide Range of Diseases^a

Tissue/Physiology	Condition	Defect
Bladder	Detrusor underactivity	C
Eye	Glaucoma Macular degeneration	C, E C, E
Vascular	Hypertension	C,E
Lung	Asthma, COPD Fibrosis, emphysema	C, E E
Brain	Traumatic brain injury	C,E
Oncology	Cancer Metastasis	C, E C
Reproductive	Pre-eclampsia	C, E
Skin	Scleroderma	E
Aging		C, E

^aAdapted from Ingber [104]